68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors
NCT01980732 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2017-08-23
Summary
The primary objective of the study is to evaluate 68Ga-DOTA TATE PET/CT for staging and monitoring response to chemotherapy in patients with carcinoid, neuroendocrine tumors, medullary thyroid cancer and other cancers expressing somatostatin receptors.
Conditions
- Carcinoid Tumors
- Islet Cell (Pancreatic NET)
- Other Neuroendocrine Tumors
Interventions
- DRUG
-
68Ga-DOTA TATE
Patients with somatostatin receptor positive tumors will be evaluated with 68Ga-DOTA TATE PET/CT in addition to conventional imaging.
Sponsors & Collaborators
-
Andrei Iagaru
lead OTHER
Principal Investigators
-
Andrei Iagaru · Stanford University
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
Countries
- United States
Study Locations
More Related Trials
-
A Study to Evaluate a New Way to Identify/Diagnose Tumours With Somatostatin Receptors Using [68]Ga-HA-DOTATATE and to Ensure it is Safe to Use
NCT03145857 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Dual SSTR2 and Integrin αvβ3 Targeting PET/CT Imaging
NCT02817945 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Use of 68Ga-dotatate PET Scan in Neuroendocrine Carcinoma of the GI Tract
NCT04069299 ·Status: COMPLETED
-
68Ga-DOTATATE PET/CT in Neuroendocrine Tumor
NCT04041882 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Diagnosis and Staging of Neuroendocrine Tumors (NETs) Utilizing 68Ga-DOTATOC PET/CT Scan
NCT03136328 ·Status: COMPLETED ·Phase: PHASE3
-
DOTATOC PET/CT for Imaging NET Patients
NCT03583528 ·Status: ACTIVE_NOT_RECRUITING
-
[68 Ga]-DOTANOC PET/CT in GEP-NETs
NCT02608203 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors
NCT01967537 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of [18F]Fluoroethyl Triazole Labelled [Tyr3]-Octreotate Analogues for the Imaging of Neuroendocrine Tumours.
NCT06456723 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
68Ga-HA-DOTATATE PET/CT in Adults With Neuroendocrine Tumors
NCT05673031 ·Status: RECRUITING
-
68Ga-HA-DOTATATE Imaging of Suspected Somatostatin Receptor Positive Tumors
NCT04888481 ·Status: RECRUITING ·Phase: PHASE2
-
AMT-PET in Monitoring Telotristat Etiprate Treatment in Participants With MetastaticNeuroendocrine Neoplasm
NCT03453489 ·Status: COMPLETED ·Phase: PHASE2
-
Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors
NCT02441062 ·Status: COMPLETED ·Phase: PHASE2
-
68Ga-DOTA-TATE PET/CT Imaging in NETs
NCT04847505 ·Status: RECRUITING ·Phase: PHASE3
-
A Prospective, Open-label Study of [68Ga]Ga-DOTA-TATE in Patients With Neuroendocrine Neoplasms (NENs) and Healthy Volunteers in Japan
NCT06240741 ·Status: COMPLETED ·Phase: PHASE3
-
[68Ga]DOTATATE-PET/MRI in Hepatocellular Carcinoma
NCT03648073 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Somatostatin Receptor PET/CT in SSTR-Related Disease Patients
NCT06690957 ·Status: RECRUITING
-
68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors
NCT03001349 ·Status: TERMINATED ·Phase: EARLY_PHASE1
-
Applying PET/MR in Neuroendocrine Tumors - Imaging Dynamic Processes in Both Modalities
NCT04152928 ·Status: UNKNOWN ·Phase: NA
-
Impact of Peptides and Chelators on Somatostatin Receptor Antagonists
NCT04491851 ·Status: UNKNOWN ·Phase: PHASE2
-
68Ga-DOTATATE PET-CT for Diagnosis of Neuroendocrine Tumors (NETs)
NCT01879657 ·Status: COMPLETED ·Phase: NA
-
18F-AmBF3-TATE PET/CT for Imaging NET Patients
NCT04207762 ·Status: COMPLETED
-
68Ga-DOTATATE PET Scan in Neuroendocrine Cancer
NCT01396382 ·Status: COMPLETED ·Phase: PHASE2
-
SSTR PET/CT for Preoperative N Stage Evaluation in GEP-NETs
NCT06344832 ·Status: NOT_YET_RECRUITING
-
68Ga-DOTATOC for Imaging of Neuroendocrine Tumors: Expanded Access Trial
NCT02358018 ·Status: NO_LONGER_AVAILABLE